NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
15 trialsNCT03840200 2023-10-30
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
Hoffmann-La Roche
Phase 1 Completed
NCT04179396 2023-06-29
RAMP
pharmaand GmbH
Phase 1 Completed
NCT02042378 2023-06-13
A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
pharmaand GmbH
Phase 2 Completed
NCT01891344 2023-06-12
ARIEL2
pharmaand GmbH
Phase 2 Completed
NCT01482715 2023-06-09
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
Phase 1/2 Completed
NCT01968213 2023-06-09
ARIEL3
pharmaand GmbH
Phase 3 Completed
NCT02855944 2023-06-09
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
Phase 3 Completed
NCT02935634 2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2 Completed
NCT02952534 2023-06-09
TRITON2
pharmaand GmbH
Phase 2 Completed
NCT03499444 2023-06-09
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
pharmaand GmbH
Phase 1 Completed
NCT03521037 2023-06-09
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
pharmaand GmbH
Phase 1 Completed
NCT01009190 2023-06-08
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
pharmaand GmbH
Phase 1 Completed
NCT03954366 2023-06-08
Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives
pharmaand GmbH
Phase 1 Completed
NCT03101280 2020-10-22
A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed